The future of CTCL therapy
4 Mga view
• 08/09/23
0
0
I-embed
administrator
Mga subscriber
Martine Bagot, MD, PhD, Hôpital Saint Louis, Paris, France, suggests how the therapeutic landscape of cutaneous T-cell lymphoma (CTCL) may evolve in the future, with the development of novel monoclonal antibodies, oncogenic peptides, and agents targeting overactivated signaling pathways in CTCL. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
Magpakita ng higit pa
Mga Komento sa Facebook
SORT BY-
Mga Nangungunang Komento
-
Pinakabagong komento